Showing results (121-130 of 172) with videos related to

Sort By:
Pageof 18
Cancers|October 28, 2023
The T Cell Immunoscore as a Reference for Biomarker Development Utilizing Real-World Data from Patients with Advanced Malignancies Treated with Immune Checkpoint InhibitorsIslam Eljilany, Payman Ghasemi Saghand, James Chen, et al.
Journal for Immunotherapy of Cancer|January 25, 2022
Improved prognosis and evidence of enhanced immunogenicity in tumor and circulation of high-risk melanoma patients with unknown primaryAhmad A Tarhini, Sandra J Lee, Aik-Choon Tan, et al.
Cancer Research|December 18, 2013
PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8⁺ T cells induced by melanoma vaccinesJulien Fourcade, Zhaojun Sun, Ornella Pagliano, et al.
Lung Cancer (Amsterdam, Netherlands)|July 16, 2013
A multicenter phase II study of cetuximab in combination with chest radiotherapy and consolidation chemotherapy in patients with stage III non-small cell lung cancerS S Ramalingam, A Kotsakis, A A Tarhini, et al.
JAMA Oncology|November 23, 2022
Effectiveness of Adjuvant Pembrolizumab vs High-Dose Interferon or Ipilimumab for Quality-of-Life Outcomes in Patients With Resected Melanoma: A Secondary Analysis of the SWOG S1404 Randomized Clinical TrialJoseph M Unger, Amy Darke, Megan Othus, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 20, 2025
Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-Risk MelanomaAhmad A Tarhini, Alyssa Obermayer, Sandra J Lee, et al.
Cancer|October 22, 2025
Overall side-effect bother consistently associated with early treatment discontinuation due to adverse events in four clinical trials with various cancer types and treatmentsJohn Devin Peipert, Shaili Ganatra, Fengmin Zhao, et al.
Cancer|May 5, 2017
Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non-small cell lung cancerAhmad A Tarhini, Imran Rafique, Theofanis Floros, et al.
Molecular Cancer Therapeutics|April 24, 2024
First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0Joseph Markowitz, Michael Shamblott, Andrew S Brohl, et al.
Cancer|March 24, 2017
A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607)Kevin Kalinsky, Sandra Lee, Krista M Rubin, et al.
Pageof 18